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LABORATORIAL DIAGNOSIS OF 
FRAGILE-X SYNDROME
Experience in a sample of individuals with 
pervasive developmental disorders
Carlos Eduardo Steiner1, Marilisa Mantovani Guerreiro2,
Antonia Paula Marques-de-Faria1, Iscia Lopes-Cendes1
ABSTRACT - Fragile X syndrome is a frequent genetic disease associated to developmental disorders, includ-
ing learning disability, mental re t a rdation, behavioral problems and pervasive developmental disord e r s
(autism and related conditions). We studied a sample of 82 individuals (69 males and 13 females) pre s e n t-
ing with pervasive developmental disorders using three techniques for the diagnosis of fragile X syndro m e
(FXS). Cytogenetic analysis detected the fragile site in four males, but only one showed a consistent posi-
tive rate. Molecular study based on the PCR technique was inconclusive for most females (92.3%), which
w h e re latter submitted to Southern blotting analysis, and for one male (1.4%), excluding the FRAXA muta-
tion in the remaining male individuals (98.6%). Molecular tests using the Southern blotting technique con-
f i rmed only one positive case (1.2%) in a male subject. These results showed that Southern blotting analy-
sis of the FRAXA mutation has the best sensitivity and specificity for the diagnosis of FXS but also validat-
ed the PCR technique as a confinable screening test. 
KEY WORDS: PCR, molecular diagnosis, FRAXA, autism, mental retardation, pervasive developmental dis-
orders.
Diagnóstico laboratorial da síndrome do cromossomo X frágil: experiência em uma amostra de
indivíduos com distúrbios invasivos do desenvolvimento
RESUMO - A síndrome do cromossomo X frágil (SXF) é uma doença genética freqüente associada a distúr-
bios do desenvolvimento neurológico, incluindo dificuldades de aprendizagem, re t a rdo mental, pro b l e-
mas comportamentais e distúrbios invasivos do desenvolvimento (autismo e correlatos). Estudamos uma
amostra de 82 indivíduos (69 homens e 13 mulheres) apresentando distúrbios invasivos do desenvolvimen-
to, utilizando três técnicas para o diagnóstico da SXF. A análise citogenética detectou a presença do sítio
frágil em quatro homens, porém apenas um deles com percentagem consistente. O estudo molecular basea-
do na técnica da PCR foi inconclusivo para a maioria das mulheres (92,3%), as quais foram posteriorm e n t e
submetidas a análise por Southern blotting, e para um homem (1,4%), excluindo a mutação FRAXA nos
demais homens (98,6%). O teste molecular usando a técnica de Southern blotting confirmou apenas um
caso positivo (1,2%) em um indivíduo do sexo masculino. Tais resultados mostraram que a técnica de
S o u t h e rn blotting para análise da mutação FRAXA apresenta a melhor sensibilidade e especificidade para
o diagnóstico da SXF, mas também valida a técnica da PCR como um teste confiável para seu rastreamento.
PA L AV R A S - C H AVE: PCR, diagnóstico molecular, FRAXA, autismo, re t a rdo mental, distúrbios invasivos do
desenvolvimento.
Fragile X syndrome (FXS) was inittialy re p o rt-
ed in 1943 by Martin and Bell1 in a large family
showing X-linked mental re t a rdation. The first lab-
oratorial method for its diagnosis was described
by Lubs in 19692, who observed a fragile site [fra
(X)] at Xq27-28 in samples cultured in folic acid
deficient medium. After that, several diff e rent fra-
gile sites were described in the same chro m o s o-
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mal region, denominated FRAXA, FRAXD, FRAXE,
and FRAXF. FRAXA is the most common of these
sites and it is associated with mutations in the
FMR1 gene, responsible for the FXS, while FRAXE
(associated to the FMR2 gene) causes non-specif-
ic mental re t a rdation and FRAXF seems to cause
no abnormal phenotype3 , 4. The molecular basis of
FXS was discovered in the early 1990´s5-8 and con-
sists of a dynamic mutation characterized by ex-
pansions of an unstable CGG repeat in the 5´ end
of the FMR1 gene. It was found that normal indi-
viduals have 6 to 54 repeats (normal allele) where-
as affected individuals present more than 200
repeats (expanded allele or full mutation). In addi-
tion, phenotypically normal male and female car-
riers were found to have intermediate size alleles
(pre-expanded alleles or pre-mutation).
FXS has a prevalence of one per 50009, re p re-
senting one of the most common genetic disor-
ders. Its clinical spectrum comprises some somatic
changes, such as macro c e p h a l y, large testes, mar-
phanoid build habitus, long face, and pro t ru d i n g
jaw. These features are only identifiable or more
p ronounced in males after pubert y. Cognitive im-
p a i rment is present, ranging from speech delay
and learning disability to severe mental re t a rd a-
tion. Besides, behavioral signs may be present, in-
cluding hyperactivity, self-biting, poor eye contact,
shyness, stereotyped movements, and other autis-
tic feature s1 0 , 1 1. This wide range of symptoms may
lead the clinician to consider the diff e rential diag-
nosis of FXS in several situations, especially among
individuals with diff e rent abnormalities of the neu-
rological development, including the pervasive de-
velopmental disorders (PDDs), a group that com-
prises autism, atypical autism, and Asperger syn-
drome.
We undertook the present study aiming to com-
p a re cytogenetics, PCR and Southern blotting tech-
niques for the laboratory diagnosis of FXS in a sam-
ple of individuals with PDDs diagnosed by the DSM
-IV criteria. These techniques were applied since
both, chromosomal abnormalities and the FXS, are
i m p o rtantetiological factors in this group of neu-
ropsychiatric conditions.
METHOD
We evaluated a total of 82 patients (69 males and
13 females) with PDDs from the Genetics and Neuro l o g y
Clinics of our University Hospital. Parents or legal guar-
dians were invited to join the study by signing a con-
sent form approved by a Research Ethics Committee.
After clinical evaluation, blood samples were collected
for cytogenetic and molecular tests. All patients were
also submitted to screening for inborn errors of metab-
olism, TORCH sorologies, and neuroimaging studies1 2.
T h ree individuals with clinical diagnosis of Down syn-
d rome were also tested for the FXS due to the possibil-
ity of co-occurence of both disorders, considering their
high incidence in the general population.
C h romosomal analysis followed the routine cytoge-
netic temporary culture in folic acid deficient medium
(M-199, with addition of 5-fluoro-2’-deoxyuridine 0.0025
mg/ml). The cultures were incubated for 96 hours at
37ºC for the expression of the fra(X) site. The cell divi-
sions were arrested in metaphases by adding colchicine
4 x 1 0- 5 M for 30-40 minutes before harvesting the cul-
t u res. The samples were fixed in a solution of 3:1 metha-
nol-acetic acid, spread in slides, and submitted to G-ban-
ding technique. Manual analysis in light microscope in-
cluded at least 50 metaphases in male and 100 in female
subjects13.
For the molecular investigation we initially used the
polymerase chain reaction (PCR) technique for specific
amplification of the CGG repeat in the 5´end of the F M R 1
gene, according the protocol described by Fu et al.6.
After amplification, the samples were submitted to elec-
t ro p h o resis in a 1.8% agarose gel at 24 V for 15 hours
together with a 250 bp molecular weight marker. Sam-
ples were then transferred into Hybond N+ nylon mem-
branes and hybridized with an -3 2P 3´-end labeled
(CGG)6 probe.
To confirm the PCR results in all subjects and to inves-
tigate the female patients, a second molecular test based
on the Southern blotting technique was used. Samples
w e re submitted to digestion with Pst I and Eco RI re s t r i c-
tion enzymes. The resulting fragments were separated
by electro p h o resis in 0.8% agarose gel at 15 V for 16
hours together with a 1 kb molecular weight marker.
After that, samples were transferred into Hybond N+
nylon membranes and hybridized with the pfxa3 pro b e
(Oncor®) marked with an -32P isotope14,15.
RESULTS
Table 1 shows the comparative findings obtain-
ed with the three techniques, as well as corre l a-
tion with gender and the specific PDD diagnosis.
Cytogenetic analysis (Fig 1) revealed the fra(X) in
four patients with autism, three of them with low
f requency (1%, 4%, and 2%) and only one patient
with a significant positive result (17%). Kary o t y p e
was altered in other six individuals, including thre e
patients with trisomy 21 and autism, one patient
with a maternally inherited pericentric inversion
of a chromosome 9 [inv(9)(p11q11)mat] and atyp-
ical autism, one patient with a maternally inher-
ited Robertsonian translocation 15/21 [ro b ( 1 5 ; 2 1 )
(p10q10)mat] and atypical autism, and one patient
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showing an increased length in constitutive hete-
ro c h romatin of the long arm of the Y chro m o s o m e
( Yqh+) and autism. All the subjects with abnorm a l
cytogenetic findings were males.
Molecular studies based on the PCR technique
revealed the presence of normal size alleles in all
Fig 1. Fragile site at Xq27.3 (arrow) as observed in the kary -
otype of individual E.C.M.
male subjects except for one patient, thus exclud-
ing the presence of mutations in most individuals.
The only individual with inconclusive PCR re s u l t s
after repeated experiments is the same who pre-
sented 17% of fra(X) cells in the chromosomal ana-
lysis (Fig 2). The remaining three male individuals
with low percent of fra(X) cells in the cytogenet-
ic analysis showed normal CGG alleles. In the fe-
males group, most patients showed only one band
in the normal size range with the exception of one
patient who showed two distinct bands in the nor-
mal size range. The observation of only one nor-
mal size band in females may indicate that the in-
dividual is homozygote for the normal allele. Ho-
w e v e r, the presence of an expanded allele, which
was not identified by this PCR technique, cannot
be definitively excluded.
The only patient with a consistent positive fra
(X) by cytogenetic evaluation was found to have
the FMR1 gene mutation by Southern blot analy-
sis. We found that this patient was a mosaic for
an expanded allele ranging from appro x i m a t e l y
100 to 900 CGG repeats (Fig 3).
Table 1. Results according to the three techniques used for the laboratory diagnosis of the FXS and correlation with
gender and the pervasive developmental disorder (PDD) diagnosis.
PDD PCR Southern blotting
Patient (gender) diagnosis Cytogenetics CGG alleles FRAXA
T.L.B.S. (male) autism fra(X) 1% normal normal
E.C.S. (male) autism fra(X) 4% normal normal
C.R.T.S. (male) autism fra(X) 2% normal normal
E.C.M. (male) autism fra(X) 17% no PCR product expanded
E.C.C. (male) atypical autism rob(15;21) normal normal
M.C.X.A. (male) atypical autism inv(9) normal normal
D.G.M.D. (male) autism 46,Xyqh+ normal normal
J.A.B.G. (male) autism 47,XY,+21 normal normal
J.V.S.A. (male) autism 47,XY,+21 normal normal
T.V.S. (male) autism 47,XY,+21 normal normal
other 46 males autism normal normal normal
6 females autism normal normal normal
other 5 males atypical autism normal normal normal
4 females atypical autism normal most inconclusive* normal
8 males Asperger syndrome normal normal normal
3 females Asperger syndrome normal normal normal
* PCR results were definitive in only one female by showing the presence of two normal size bands.
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DISCUSSION
FXS may be present in about 0.8% of persons
with autism1 6, 0.5% of pre-scholars with speech
d e l a y1 7, 0.56% of individuals with mental re t a rd a-
t i o n1 8, and 0.9% of subjects with non-specific men-
tal re t a rd a t i o n1 9. At first these frequencies may seem
too low to justify laboratory testing for FXS in these
patients. However, it is important to note that these
conditions are very common in the general popu-
lation and early intervention has a great impact
in prognosis. In addition, the diagnosis of FXS is
v e ry important for adequate genetic counseling of
the couple and, in extension, to other maternal re l-
atives. Thus, laboratory detection of FXS is indi-
cated in the etiological investigation of individu-
als presenting abnormalities in behavior, language,
socialization or cognitive development, including
the pervasive developmental disorders group.
Fig 2. Molecular study based on the PCR technique showing pictures of the gel (A) and of
the X-ray film obtained after autoradiography (B). Note the absence of PCR products in ro w
7, the presence of two distinct bands in row 11, and the presence of a single band re p re s e n t -
ing normal alleles in the remaining rows. Row 5 corresponds to the molecular weight mark -
er (250 bp).
Fig 3. Molecular analysis following enzymatic digestion and Southern blotting. Normal alle -
les are shown is rows 1 to 5. A positive control female carrier is shown in row 6. Row 7 cor -
responds to patient E.C.M. presenting a mosaic pattern for the expanded CGG allele in the
FMR1 gene; “mpm” refers to the molecular weight marker Generuler® 1 kb.
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Since the discovery of the molecular basis of
FXS, cytogenetic tests for its diagnosis have been
less used but were not totally abandoned. Sou-
t h e rnblotting technique is the most used labora-
torial method but several alternative approaches
have been developed in the last decade. These in-
clude PCR with radioactive probe or silver stain,
reverse transcription PCR (RT-PCR), methylation-
sensitive PCR (MS-PCR), and immunohistochemi-
cal analyses. As for any laboratory technique a
number of methodological issues are involved in
the accurate diagnosis of FXS. The advantages and
disadvantages of each method we used in the pre s-
ent work are summarized on Table 2.
Among the three techniques, cytogenetic analy-
sis showed the highest rate of altered results in t h e
present sample by the detection of three individ-
uals presenting structural chromosomal abnorm a l-
ities that could not be diagnosed by m o l e c u l a r
study of the FRAXA mutation alone. One oft h e m
showed an increased length on the long arm of
chromosome Y, which has been previously repor-
ted in association with autism2 0. Another patient
had a pericentric inversion of chromosome 9, situa-
tion that recent literature data suggest may be in-
volved in genetic susceptibility to psychiatric disor-
ders such as schizophrenia or even autism2 1. The
third one presented a roberstonian translocation
15/21 and, again, literature data suggest that ab-
n o rmalities of chromosome 15 have a higher p re v a-
lence in autism than in the general population22.
Considering the technical aspects of cytogenet-
ic analysis for FSX, usually a longer exposure to
colchicine causes more chromosomal condensa-
tion, which turns fra(X) easier to be detected by
microscopic analysis. We used a shorter exposure
(30 to 40 minutes instead of 60 minutes) which is
less likely to interf e rewith the detection of other
cytogenetic abnormalities. Although cytogenetic
evaluation was sensitive and specific for the diag-
nosis of FXS, the fact that it is based in a 96-hours
cell culture, which can fail, may re q u i rere - t e s t i n g
in several occasions. When the culture is success-
ful, the study demands many hours of micro s c o p-
ic analysis, especially for the female specimens. In
addition, it is well known that this method may
not detect all carrier females, and would miss most
male carriers, since only a small pro p o rtion of their
cells will express the fra(X)10. The best advantage
of this method is that it makes it possible to detect
other chromosomal abnormalities, including the
other fragile X sites with one single test.
PCR is a rapid and versatile method for ampli-
fying a target DNA sequence. Because it is a fast
and simple method, PCR is ideally suited for muta-
tion screening since it can yield results in a single
day experiment. However, the optimal size range
for PCR amplification is between 0.1 to 5 kb, which
may limit its application. The size of the band on
the gel corresponding to a fragment with norm a l
CGG repeat in the FMR1 gene has approximately
250-300 bp and it will be easily amplified in the
PCR experiments. However, the expanded CGG
allele may be too large and fail to amplify. There-
f o re, a male with a normal allele will be re a d i l y
identified by PCR as having only one single band
Table 2. Advantages and disadvantages of each method for the laboratorial diagnosis of the FXS.
Method Advantages Disadvantages
Cytogenetics Analysis of all chromosomes, allowing the Time consuming
identification of structural and numerical Risk of false negative results
abnormalities besides the fragile site Does not differentiate FRAXA from FRAXE
Does not detect carriers
Does not identify point mutations
PCR Quick result Confinable only for non-FXS males
Uses small amount of DNA Not informative for female subjects and affected males
Dispenses the use of radioisotopes (thus Risk of false inconclusive results
reducing custs and becoming feasable in Risk of non detecting carriers
less equiped laboratories) Does not identify point mutations
Southern blot Confiable for male and female subjects, Time consuming and expensive
including carriers Uses large amount of DNA
Includes radioactive step
Does not identify point mutations
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in the normal size range (250-300 bp). On the oth-
er hand, the absence of bands could indicate that
the individual has an expanded allele or that a
technical problem occurred to interf e re in the opti-
mal amplification of the normal allele. There f o re ,
the PCR technique can easily identify normal alle-
les, but usually is not efficient for the detection of
the expanded CGG alleles.
In our study, only one patient who had positive
cytogenetic study had an altered PCR result. The
t h ree individuals with low percentage of fra(X)
cells in the cytogenetic study had single norm a l
CGG alleles, thus excluding the FRAXA mutation
which was also confirmed by the Southern blot-
ting analysis. 
In females, normal PCR fragments with similar
sizes will result in a single band, making it impos-
sible to diff e rentiate normal homozygote female
f rom a carrier of the FXS mutation. In our study
the PCR technique was not informative for most
females, since only a single individual was het-
e rozygote for the normal CGG, and consequently
a normal non-carrier FRAXA subject. Considering
this, Weinhäusel and Haas2 3 described an altern a-
tive PCR technique using fluorescence analysis
called methylation-sensitive PCR (MS-PCR) that was
useful for the detection of carrier females, altho-
ugh distinction between pre-mutated and fully
mutated females was sometimes difficult in their
experience. In addition, it is important to note
that, in order to confirm that the band in the gel
t ruly corresponded to the CGG fragment, transfer
and hybridization with specific radioactive pro b e s
were performed after the gel electrophoresis. As
t h e re was no other bands in our experience, we
concluded that transfer and hybridization was
u n n e c e s s a ry and that the analysis can be accom-
plished by agarosis gel electro p h o resis stained with
ethidium bromide, without the necessity of use of
radioisotopes.
F i n a l l y, Southern blotting gave informative re-
sults for all patients and confirm that only one in-
dividual had the FRAXA mutation. It also lead to
i n f o rmation in all females tested. However, this
technique requires large amounts of well preser-
ved DNA (approximately 50 µg) and it demands a
week of laborious laboratory work to complete
all the technical steps re q u i red, including isotope
manipulation.
These results are similar to those of Haddad et
a l .2 4 who also studied a sample of Brazilian boys
with mental re t a rdation using the Southern blot-
ting technique and the PCR technique of Fu et al.6
modified by the use of silver staining instead of
labeling with an isotopic probe. In their study, a
boy with mosaicism including pre-mutated and
fully mutated allele was also re p o rted and showed
d i s c repant results in sequenced PCR tests, which
was not seen in our work.
A final problem, common to the all three tech-
niques discussed, is that point mutations in the
FMR1 gene will not be detected by any of them.
F o rt u n a t e l y, this is a rare situation in FXS2 5, and
can be diagnosed only by gene sequencing. This
a p p roachshould be considered if the diagnosis of
FXS is highly probable and all other diagnostic
techniques failed.
The specific digestion followed by Southern
blotting showed the best sensitivity and specifici-
ty for the laboratory diagnosis of FXS and also
allowed the detection of possible female carr i e r s .
H o w e v e r, if only this technique was used it would
have missed the six patients with chro m o s o m a l
a b n o rmalities, an important group of etiologic
factors of mental re t a rdation. Thus, we suggest
that this method should only be the first choice
when the clinical diagnosis of FXS is highly prob-
able or to investigate relatives of confirmed FXS
subjects (especially females) for genetic counsel-
ing and prenatal diagnosis. In individuals pre s e n t-
ing developmental disorders in which the diagno-
sis of FXS is probable but not the main hypothe-
sis, chromosomal analysis should always be perf o r-
med. Considering that small structural abnorm a l-
ities can be detected only in prometaphasic chro-
mosomes, this type of preparation is re c o m m e n d-
ed. On the other hand, this pro c e d u rewill make
it more difficult to detect fra(X). 
In conclusion, we stress the importance of cyto-
genetic analysis as a necessary tool to investigate
individuals with developmental disorders. It should
be perf o rmed in male and female subjects, pre f e r-
able with techniques that allow high chro m o s o m a l
resolution. To complement the investigation of the-
se individuals, molecular analysis based on the PCR
technique may be used as a screening test for male
subjects since it is enough to exclude the FRAXA
mutation in most of them, who are expected to be
not affected by the FXS. In female subjects and in
males with a major indicative of FXS or when the
PCR method was not informative, the Southern
blotting technique should be the method of choice
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Fig. 4. Proposed algorithm for the laboratory diagnosis in Brazil
of fragile X syndrome in male and female individuals with deve -
lopmental disorders. These molecular tests are re c o m m e n d e d
to follow cytogenetic analysis, screening for inborn errors of
metabolism, TORCH sorologies, and neuroimaging as part of
the complementary evaluation of individuals with disorders of
neurological development.
(Fig 4). The diagnostic strategy we propose, a l-
though not in accordance with other intern a t i o n-
al guidelines for the laboratorial diagnosis of the
FXS, re p resents a reasonable approach in Brazil, a
c o u n t ry with limited access of families to clinical
genetics services, heterogeneous distribution and
conditions of laboratories, and limited govern m e n-
tal re s o u rces for medical genetics serv i c e s .
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